QC
RVMD icon

Quantessence Capital’s Revolution Medicines RVMD Stock Holding History

Quantessence Capital’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-86,510
Closed -$3.18M – 287
2025
Q2 		$3.18M Buy
+86,510
New +$3.32M 0.94% 20

Other funds holding RVMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Quantessence Capital's RVMD Position: Q3 2025 in Review

Quantessence Capital sold out of Revolution Medicines (RVMD) in Q3 2025, closing a stake of 86,510 shares — an estimated $3.18M sold.

Quantessence Capital first reported a position in RVMD in Q2 2025 and held it in 1 quarter. The position peaked at $3.18M in Q2 2025. 323 funds tracked by Wall St. Rank hold RVMD as of Q3 2025.

  • Quantessence Capital reported no remaining Revolution Medicines position as of Q3 2025 after selling out during the quarter.
  • Quantessence Capital sold 86,510 Revolution Medicines shares in Q3 2025, an estimated $3.18M.
  • Quantessence Capital first reported a position in Revolution Medicines in Q2 2025 and held it in 1 quarter.
  • Quantessence Capital's Revolution Medicines position peaked at $3.18M in Q2 2025.
  • 323 funds tracked by Wall St. Rank held Revolution Medicines as of Q3 2025.

Based on Quantessence Capital's 13F filing for Q3 2025, filed 14 Nov 2025.